GPI-1485 (Guilford)

Curr Opin Investig Drugs. 2004 Jan;5(1):107-12.

Abstract

GPI-1485 is a neuroimmunophilin ligand that binds to FK-506-binding proteins and is under development by Guilford for the potential treatment of erectile dysfunction following nerve injury during prostate resection and Parkinson's disease. In August 2002, phase II clinical trials investigating GPI-1485 for Parkinson's disease commenced, and in November 2003, further phase II trials commenced for post-prostatectomy erectile dysfunction.

Publication types

  • Review

MeSH terms

  • Administration, Oral
  • Animals
  • Antiparkinson Agents / chemistry
  • Antiparkinson Agents / pharmacokinetics
  • Antiparkinson Agents / therapeutic use*
  • Clinical Trials, Phase II as Topic
  • Erectile Dysfunction / drug therapy
  • Erectile Dysfunction / etiology
  • Humans
  • Male
  • Parkinson Disease / drug therapy
  • Patents as Topic
  • Prostatectomy / adverse effects
  • Structure-Activity Relationship
  • Tacrolimus / analogs & derivatives
  • Tacrolimus / chemistry
  • Tacrolimus / pharmacokinetics
  • Tacrolimus / therapeutic use*

Substances

  • Antiparkinson Agents
  • GPI 1485
  • Tacrolimus